An Open-label, Randomised, 3-way Crossover Single Dose Study to Demonstrate Dose Proportionality of Fluticasone Furoate (FF) and Equivalence of Vilanterol (VI) When Administered as FF/VI Inhalation Powder From the Novel Dry Powder Inhaler in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 04 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Oct 2010 Actual initiation date (October 2010) added as reported by ClinicalTrials.gov.